inotuzumab ozogamicin

(redirected from CMC-544)

inotuzumab ozogamicin

A humanised CD22 linked to calicheamicin, which is being studied as a possible therapy for acute lymphoblastic leukaemia. Early data suggests that it can induce the desirable apoptosis of malignant cells at lower doses than those required for the CD33 immunotoxin gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia,
References in periodicals archive ?
Inotuzumab ozogamicin, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells.
AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID, Bortezomib, CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone, SGN-30, SGN-40, Temsirolimus, Zanolimumab.